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Abstract 
Background: Inflammatory bowel diseases patients eligible for biological therapy 
represent a group with considerable disease burden and biologics only achieve 40% 
clinical remission rates in responders after 1 year of therapy. 
Aims: To collect all the published data about patients treated with dual biological 
therapy with an Anti-TNF, vedolizumab or ustekinumab, for a period of at least 3 
months and to pool the data about the effectiveness and safety. 
Methods: A MEDLINE, and Web of Science search of all studies published in English 
until January 1, 2019 was conducted.  
Results: We included 7 studies with a total of 18 patients. Fifteen patients were 
treated with a combination of an anti-TNF and vedolizumab, 3 patients were treated 
with vedolizumab and ustekinumab. Fifty-six percent of patients were affected by 
Crohn’s disease and 50% of patients were treated with an immunosuppressant drug 
or steroid too. A clinical improvement was obtained in 100% of patients, and an 
endoscopic improvement in 93% of patients. No serious adverse events were 
reported.  
Conclusions: The use of dual biological therapy is an attractive therapeutic option 
and may be an opportunity to better tailor and personalize the therapies for patients. 
Further studies, as randomized control trials, to provide comparative efficacy and 
safety endpoints of combination therapies, and to clarify potential advantages of 
combined biological therapies, are needed.  
 
Key Words: Anti-integrin; Biologics; Crohn’s disease; Inflammatory bowel disease; 
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1 Introduction: 
Inflammatory bowel diseases (IBD) patients eligible for biological therapy represent a 
group with considerable disease burden who have failed conventional medication 
such as corticosteroids and thiopurines and therefore are at high risk of surgical 
intervention. In these patients, biologic agents only achieve approximately 40% of 
clinical remission rates in responders after 1 year of therapy [1]. 
Given the extensive redundancy of the inflammatory network, concomitant use of 
two different biologics may combine different mechanisms of action. 
Most of the experience in Crohn’s disease (CD) and ulcerative colitis (UC) have 
relied on the combination of targeted biologics with immunomodulators [2], but there 
is a lack of information regarding the effects of long-term combination of biological 
therapies in IBD. 
A recent narrative review [3] included no studies about patients with active IBD 
treated with a combination of two among an Anti-TNF effective in IBD, vedolizumab 
or ustekinumab for a period of at least 3 months. 
The aim of this systematic review is to collect all the published data about patients 
treated with a combination of two among an Anti-TNF effective in IBD (i.e. we 
excluded etanercept), vedolizumab or ustekinumab for a period of at least 3 months 
and to pool the data regarding the effectiveness and safety of this therapeutic 
strategy. 
 
2 Materials and methods:  
Articles published in English, about the use of dual biological therapy in IBD, were 
identified through PubMed and Web of Science (“All databases”) searches using the 
terms “infliximab[Title] AND vedolizumab[Title]”, “infliximab[Title] AND 
ustekinumab[Title]”, “adalimumab[Title] AND vedolizumab[Title]”, “adalimumab[Title] 
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AND ustekinumab[Title]”, “certolizumab[Title] AND vedolizumab[Title]”, 
“certolizumab[Title] AND ustekinumab[Title]”, “golimumab[Title] AND 
vedolizumab[Title]”, “golimumab[Title] AND ustekinumab[Title]”, “anti-TNF[Title] AND 
vedolizumab[Title]”, “Anti-TNF[Title] AND Ustekinumab[Title]”, “vedolizumab[Title] 
AND ustekinumab[Title]”. The final date of the search was January 1, 2019.  
Reference lists from published articles were also employed, such as citing articles on 
PubMed Central. Titles of these publications and their abstracts were scanned in 
order to eliminate duplicates and irrelevant articles.   
The inclusion criteria were: 
a) original studies; 
b) active IBD; 
c) combination treatment with an Anti-TNF, vedolizumab or ustekinumab; 
d) duration of co-treatment: at least three months; 
e) data about clinical or endoscopic IBD improvement. 
The inclusion criteria were: 
a) combination treatment with etanercept. 
There was no restriction for the study design type or the sample size. 
Two authors (D.G.R. and G.P.C.) independently reviewed titles and abstracts of 
references retrieved from the literature search and selected potentially relevant 
studies. The full-text versions of selected studies were then assessed by the two 
authors to determine whether the inclusion criteria were satisfied. Differences in 
opinion were solved by discussion until consensus was reached. If an agreement 
failed to be reached, a third author (A.M.) was consulted. 
Since only case series and case reports are available in literature, all the studies in 
agreement with the inclusion criteria were included in the systematic review and in 
the pool analysis, without a quality analysis of each study. 
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2.1 Statistical analysis 
The number of patients, their sex, the disease (UC or CD), the biologic drugs, the 
indication for dual biological therapy, the additional treatment with immunomodulator 
or prednisone, the duration of combination therapy, the onset of side effects during 
co-treatment, the clinical improvement and the endoscopic improvement were 
collected in a datasheet and pool analyzed. 
Data were tested for normality using the D’Agostino-Pearson test. If the data were 
not normally distributed, the median (range) was reported, otherwise the mean (95% 
confident interval (CI)) was reported. Categorical variables were reported as number 
(%).  
Statistical analyses were conducted using Med Calc® version 14.8.1 software. 
 
3 Results: 
The flow diagram about the studies’ identification, screening, eligibility and the 
number of the included studies is reported in Figure 1. 
 
Figure 1.  
 
3.1 Anti-TNF and vedolizumab 
The first data about the effectiveness of dual biological therapy in IBD have been 
presented by Afzali et al. at the “American College of Gastroenterology” 2016 
meeting [4]. It was a case report of a 23-year-old female with ileo-colonic and 
perianal CD previously treated with prednisone, infliximab, adalimumab, 
certolizumab. Despite ongoing treatment with vedolizumab and mercaptopurine, she 
was unable to tape the steroids, with a severe colonic disease at endoscopy, so 
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adalimumab was added. A clinical and endoscopic improvement was obtained. She 
stopped the steroids and mercaptopurine. Vedolizumab was discontinued after 6 
months and clinical remission persisted until the end of follow-up. No side effects 




The first case of UC treated with two biologics was presented by Fischer et al. in 
2017 [5]. The patient was a 33-year-old man with therapy (azathioprine, cyclosporine, 
adalimumab, infliximab, golimumab)-refractory UC. Proctocolectomy was refused by 
the patient. Sigmoidoscopy showed signs of severe inflammation. Vedolizumab was 
started, without endoscopic improvement at week 8. Since the patient developed 
spondyloarthritis, certolizumab was added. The spondyloarthritis completely resolved 
and the underlying colitis activity continuously improved with occurrence of clinical 
remission at week 16. Sigmoidoscopy was performed 21 months after initiation of the 
ongoing combination therapy with vedolizumab and certolizumab: mucosal healing 
was revealed. During the whole-treatment period no therapy-associated side effects 
occurred. 
Roblin et al. [6] reported the first case of an IBD patient co-treated with golimumab 
and vedolizumab. A 48-year-old female was affected by a severe, extensive, UC and 
ankylosing spondylitis despite previous treatment with infliximab and adalimumab. 
Disabling symptoms of ankylosing spondylitis re-emerged after 10 weeks of 
vedolizumab therapy so, given the good initial improvement of UC’ activity to 
vedolizumab, golimumab was added to vedolizumab and induced resolution of 
intestinal and axial symptoms. After 1 year of combined vedolizumab-golimumab 
treatment the patient was in clinical and endoscopic remission with no clinical activity 
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of spondyloarthritis. No adverse effects, nor infection events occurred throughout the 
year of treatment. 
The larger case series about combining Anti-TNF-α and Vedolizumab has been 
published by a Norwegian group [7]. All patients showed some effect of anti-TNF 
treatment, but they still had disease activity assessed by clinical symptoms or 
endoscopy. Six UC patients treated with infliximab and vedolizumab and 4 CD 
patients (3 patients treated with infliximab and vedolizumab and 1 patient treated with 
adalimumab and vedolizumab) were included. Three CD and 1 UC patients received 
immunomodulators at baseline and 1 UC patient received systemic corticosteroids at 
the time of inclusion. Throughout the 17 months (median) of follow-up 8 patients 
stopped anti-TNF therapy after a median of 6 months of combination therapy: all 
these patients were in clinical remission and 5 in endoscopic remission. Two CD 
patients carried on the combination treatment with vedolizumab and anti-TNF after 
20 and 19 months, respectively. In these 2 patients, treatment with anti-TNF was 
discontinued due to clinical remission after 6 and 12 months. However, anti-TNF was 
reintroduced after 4 months and 6 weeks due to the recurrence of gastrointestinal 
symptoms/arthralgia in the first patient and to the recurrence of gastrointestinal 
symptoms in the second patient. At the end of the follow-up, none of the patients 
received corticosteroids. In UC patients, endoscopic evaluation was performed at a 
median of 10 months after the start of combination treatment. Three patients showed 
endoscopic remission and 3 patients showed significant endoscopic improvement. In 
CD patients, endoscopic evaluation was performed at a median of 14 months after 
the start of combination treatment. Two patients showed endoscopic remission and 1 
patient showed significant endoscopic improvement. The fourth patient stopped 
infliximab therapy after 12 months on combination treatment when in clinical and 
biochemical remission but experienced a sudden and severe flare at 4 weeks before 
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the planned endoscopy; in this patient, no endoscopic improvement was observed.  
Regarding side effects, three patients received antibiotics for upper airway infection 
during follow-up. One UC patient experienced dyspnea 5 months after starting 
combination treatment, but clinical examination, spirometry, and pulmonary high-
resolution computed tomography revealed no pathology. The symptoms resolved 
without any treatment. 
Finally, Mao et al. [8] presented two additional cases of patients with CD treated 
with golimumab and vedolizumab.  
The first case was about a young man with stricturing ileocolonic and perianal CD, 
previously treated with azathioprine, infliximab, adalimumab, certolizumab, 
ustekinumab. At the age of 23 he required a second resection with end-ileostomy. 
Postoperatively vedolizumab was started, but he experienced disease recurrence 1 
year after initiation. Magnetic resonance enterography demonstrated inflammatory 
changes and narrowing in two segments of small bowel. At the age of 26 the patient 
was admitted to the hospital with a partial small bowel obstruction requiring 
intravenous corticosteroids despite vedolizumab therapy. In addition, golimumab was 
added to his regimen given his reluctance to pursue further surgery. During 8 months 
of dual biological therapy he developed one flare of partial small bowel obstruction 
requiring hospitalization and corticosteroids. He has successfully tapered off 
corticosteroids and considered himself in clinical remission. He didn’t experience 
infectious complications.  
The second case was a young woman with stricturing ileocolonic and perianal CD, 
previously treated with infliximab, adalimumab, certolizumab. She underwent to 
ileocolic resection and postoperatively she achieved clinical remission on 
natalizumab but developed antibodies to the John Cunningham virus and the drug 
was stopped. She failed ustekinumab and she required a second ileal resection with 
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diverting loop ileostomy for severe perianal disease, which was complicated by 
postoperative recurrence only 8 weeks after surgery, confirmed by ileoscopy 
demonstrating distal ileal and stomal ulcerations. She was treated with tocilizumab 
and then with tofacitinib, with a temporary response to the latter drug.  Given prior 
response to natalizumab, vedolizumab was initiated after ileostomy takedown. 
Tofacitinib was subsequently discontinued and switched to golimumab as the patient 
desired conception. She achieved clinical remission on this regimen, though this has 
not been confirmed endoscopically. Her first pregnancy was uncomplicated and the 
baby was delivered at term on golimumab, vedolizumab and mercaptopurine. Her 
second pregnancy, on the same medical regimen, was complicated by subchorionic 
hemorrhage and single umbilical artery, hand-foot-mouth disease that self-resolved 
and influenza despite vaccination. She delivered another normal baby at term. 
 
3.2 Vedolizumab and ustekinumab 
In 2017 Huff-Hardy et al. [9] presented the first IBD patients treated with vedolizumab 
and ustekinumab dual therapy. A 22-year-old woman was affected by a refractory 
CD, with severe colonic involvement and multiple strictures eventually requiring 
subtotal colectomy and end ileostomy. Moreover, she also developed aggressive 
penetrating disease with enterocutaneous perianal fistulas. Over the course of her 
disease, she was treated with infliximab, adalimumab, certolizumab, natalizumab, 
and vedolizumab combined with immunomodulators with poor responses, and in 
some instances, poorly tolerated side effects including infections. Ustekinumab was 
initiated because of progressive and unresponsive disease affecting her small bowel 
and rectal stump with development of perianal fistulas and severe vulvar disease. 
However, there was little subjective change in her gastrointestinal complaints and her 
vulvo-perianal disease continued to progress. Because of the unresponsive nature of 
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the disease, vedolizumab, ineffective as monotherapy in the past, was added to the 
ustekinumab and methotrexate regimen. At her 8-week follow-up the vulvo-perianal 
disease improved dramatically. She subsequently underwent completion proctectomy 
with perineal reconstruction. This patient experienced a combination therapy with 
vedolizumab, ustekinumab, and methotrexate for over 1 year and achieved deep 
remission. During the follow-up period she underwent to an episode of self-limited 
rotavirus infection.   
In the same year, Liu et al. presented a second case of a refractory ileocolonic CD 
in a 27-year-old female [10]. She underwent a right hemicolectomy at the age of 17, 
followed by small bowel resections at the age of 20 and 21 for medically refractory 
disease. She was previously treated with azathioprine, prednisone, infliximab, 
adalimumab, and ustekinumab, and she joined clinical trials testing tofacitinib and 
mongersen. She was assessed for ongoing severe CD receiving a retrial of infliximab 
with the addition of methotrexate combination therapy. Colonoscopy showed ongoing 
deep serpiginous ileal ulcers, colonic aphthous ulceration, and worsening deep rectal 
ulceration. As her previous ustekinumab therapy didn’t included intravenous loading, 
infliximab combo therapy was stopped, and she restarted ustekinumab with induction 
dosing and then subcutaneously, in combination with azathioprine. Despite this, 
symptoms continued: magnetic resonance enterography showed ongoing evidence 
of inflammation five months post initiation of ustekinumab; so vedolizumab was 
added. Five months after adding vedolizumab to ustekinumab abdominal pain and 
nausea began to improve. Colonoscopy 6 months after dual biological therapy 
showed mucosal healing of the ileum and colon. No side effects from her medical 
therapy have arisen thus far. 
The most recent case of vedolizumab and ustekinumab combination therapy was 
presented by Mao et al [8]. A young man diagnosed with colonic and perianal CD, 
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previously treated with infliximab, had a secondary loss of response despite co-
treatment with methotrexate and infliximab dose optimization. Colonoscopy 
demonstrated colitis to the hepatic flexure. Infliximab was switched to ustekinumab. 
Initially the patient demonstrated a clinical response to ustekinumab, but he 
continued to experience bloody diarrhea and nocturnal symptoms, requiring 
concurrent high-dose prednisone taper. Given his partial response to ustekinumab 
and prior mechanistic failure of anti-TNF, vedolizumab was added to ustekinumab. 
After 2 months of dual biological therapy he achieved steroid-free clinical remission. 
During 5 months of dual biological therapy he experienced two episodes of 
Clostridium difficile infection: he was treated with 2-week courses of vancomycin.  
 
3.3 Pool analysis 
A total of 18 patients have been treated with dual biological therapy. Their clinical 




The geometric mean duration of dual biological therapy has been 14 months (range = 
5-37 months). Nine out of the 18 patients (50%) were also treated with 
corticosteroids or immunosuppressants Figure 2. 
 
Figure 2.  
 
A clinical improvement was obtained in 18 out of the 18 patients (100%), an 
endoscopic improvement in 14 out of the 15 patients in which this data was available 
(93%).  Figure 3. 
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Figure 3.  
 
Seven out of the 18 patients experienced a side effect (38.9%): 3 cases of upper 
respiratory tract infections, 1 case of dyspnea, 1 case of rotavirus infection, 1 case of 
recurrent Clostridium difficile infection, 1 case of self-limited viral illnesses (hand-foot-
mouth disease and influenza despite vaccination) Figure 4. 
 
Figure 4.  
 
4 Discussion: 
Despite the introduction of new biological therapies many patients with IBD remain 
refractory to  available treatments [11]. 
This study represents the first systematic review with pool analysis about the 
effectiveness and safety of dual biological therapy in active IBD. 
Unlike the recent narrative review of Hirten et al. [3], that included no study about 
patients with active IBD treated with a combination of an Anti-TNF effective in IBD, 
vedolizumab or ustekinumab for a period of at least 3 months, we included 7 studies 
with a total of 18 patients. We excluded patients treated with etanercept, a fusion 
protein that blocks the TNF receptor without inducing lymphocyte apoptosis, since its 
ineffectiveness in the treatment of IBD; moreover it’s the drug most frequently 
implicated in this immunologic toxicity [12]. We excluded patients treated with 
natalizumab as this drug is associated with progressive multifocal 
leukoencephalopathy and is not approved for IBD in the European Union [13]. 
Most of the patients were treated with a combination of an anti-TNF and 
vedolizumab (15 out of the 18 patients), while 3 patients were treated with 
   14 
 
vedolizumab and ustekinumab. In literature the data about a dual biological therapy 
with an anti-TNF and ustekinumab report the efficacy only regarding dermatological 
associated diseases and about safety (good), but not about the efficacy on an active 
IBD [14]. 
Regarding the epidemiological characteristics of the patients treated so far, sex 
and category of IBD are almost equally distribute (56% of female, 56% of CD). 
Despite the dual biological therapy, 50% of patients were treated also with an 
immunosuppressant drug or steroid, because of the extreme difficult-to-treat 
diseases: the addition of a second biological drugs, an off-label strategy, seemed to 
be the only therapeutic chance for these patients. For example, in patients with 
numerous previous surgical interventions, at risk for short bowel syndrome, dual 
biological therapy could be considered as a surgery-sparing strategy. 
Considering the type of patients treated, often with a history of non-response or 
loss of response to all currently available drugs, a 100% rate of clinical improvement 
and a 93% rate of endoscopic improvement are more than flattering rates. 
The patients in our systematic review have been treated with dual biological 
therapy for almost 14 months, without an excess risk of serious adverse events (3 
cases of upper respiratory tract infections, 1 case of dyspnea, 1 case of rotavirus 
infection, 1 case of recurrent Clostridium difficile infection, 1 case of self-limited viral 
illnesses). The possibility of achieving clinical benefit outweighed potential adverse 
effects of dual biological therapy, especially with the favorable safety profiles of 
vedolizumab and ustekinumab. However, to confirm the data about the safety, further 
studies with larger sample sizes are warranted. 
A gut-specific anti-integrin therapy like vedolizumab has the benefit of being 
potentially safer than systemic therapies and could be the ideal drugs to be 
associated with other target therapies. Given its mechanism of action, it seems 
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reasonable to postulate that vedolizumab could be safely combined with other 
biological agents, without substantially increasing the risk of serious infections. 
In addition to outcomes consideration, economic cost will likely play an increasing 
role in the real-world application of this therapeutic strategy. Although dual biological 
agents are more expensive than immunomodulator combinations, we must consider 
that the failure of sustained clinical remission during medical therapy implies an 
increased risk of surgery, hospitalization, colorectal cancer, work disability, and 
reduced quality of life [15]. Furthermore, the possible savings associated with of 
biosimilars may offset the cost.  
In this light, a short coinduction with dual biologic agents and then transitioning to 
monotherapy could be the more suitable strategy. The onset of vedolizumab activity 
typically occurs more slowly than the activity of Anti-TNF, even several months after 
the induction of the therapy [16]. Consequently, in patients with only a partial 
improvement to Anti-TNF, a combination of Anti-TNF and vedolizumab may act as a 
bridge until the expected vedolizumab effect occurs, thereby avoiding the use of 
additional corticosteroids, which is associated with serious and sometimes 
irreversible side effects [17]. This is supported by the findings of Buer et al. [7]: 3 out 
of 10 patients received corticosteroids at some point during the combination 
treatment. According to clinical experience, more frequent use of long-term 
corticosteroids might be necessary without the combination of anti-TNF and 
vedolizumab. Furthermore, all of the UC patients could successfully stop anti-TNF 
therapy and continue with vedolizumab in monotherapy, whereas 2 out of the 4 CD 
patients were still on combination treatment at the end of the follow-up [7]. This 
finding suggests that CD patients could more often require the synergistic effect of 
combination therapy. Thus, combination treatment with anti-TNF and vedolizumab 
could represent a long-term option in selected CD patients. 
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Only a small number of patients were treated with a dual biological therapy: this is 
the major limitation of our systematic review, but these data are of paramount 
importance for a topic of potentially increasing interest in the coming years. The 
definition of clinical improvement is a weak outcome, but the extreme difficult-to-treat 
population and the correlation with a rate of 93% of endoscopic improvement give 
strength to these efficacy data. Given the small sample size sub-analyses about the 
specific biologic in use are not feasible. Despite the short-term safety seems 
promising, data deriving from a long-term follow-up, even after the dual biological 
therapy stopping, are needed. We didn’t consider in our pool analysis the adverse 
events occurred after discontinuing one of the two biologics, i.e., on biologic 
monotherapy. In particular, Anti-TNF is an effective treatment for extraintestinal 
manifestations associated with IBD, including musculoskeletal and cutaneous 
manifestations [18]. It is therefore reasonable to assume that flare of extraintestinal 
manifestations might occur in patients who discontinue Anti-TNF therapy, and it could 
be an argument for long-lasting combination treatment in selected patients. 
Increasing attention to the use of combination biological agents and the possible 
incorporation of future small molecule therapies hold great promise in closing the 
remaining therapeutic gap that exists in IBD. Furthermore, an efficacious combination 
of biological therapies would not only provide a significant therapeutic advance but 
would also offer further insights into the underlying pathogenesis of IBD. 
 
5 Conclusions:  
In conclusion, the use of dual biological therapy in IBD is an attractive therapeutic 
option: with different target-specific biologics now available and improved 
immunological understanding of IBD, there may be an opportunity to better tailor and 
personalize our therapies for patients. 
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Further studies in IBD should be developed, as randomized control trials, to 
provide comparative efficacy and safety endpoints of combination therapies, and to 
clarify potential advantages of combined biological therapies. Since the potentially 
dire consequences of untreated severe disease, patients at high risk for progression 
or affected by severe disease would likely benefit most from this early aggressive 
approach and would be an ideal initial study population. 
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Buer et  Case 6 UC Active IBD 9 Ifx-Ved 5 Yes Yes 9 Yes >6 3 U.A.I. 














































































































































CD = Crohn’s disease; Ada = adalimumab; Ved = vedolizumab; Cer = certolizumab; Gol = golimumab; Ifx = infliximab; U.A.I. = upper 
airway infection; Dysp. = dyspnea; Ust. = Ustekinumab; Rot. = rotavirus infection; CDI = Clostridium difficile infection; N/A = not 
available; SLVI = self-limited viral illnesses
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M: 8; 44 
F: 10; 56 
CD: 10; 56 
UC: 8; 44 
Ada-Ved: 2; 11.1 
Cer-Ved: 1; 5.6 
Gol-Ved: 3; 16.7 
Ifx-Ved: 9; 50 
Ved-Ust: 3; 16.7 
M = male; F = female; CD = Crohn’s disease;  
UC = ulcerative colitis; Ada = adalimumab;  
Ved = vedolizumab; Cer = certolizumab;  
Gol = golimumab; Ifx = infliximab;  
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Figure 1. Flow diagram of the study 
Figure 2. Co-treatment with immunosuppressant drugs or steroids 
Figure 3. Endoscopic improvement 
Figure 4. Rate of side effects 
 
 
 
 
 
